New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 18, 2013
10:03 EDTMKGAYMerck KGaA enters into license agreement with CNIO
Merck Serono, the biopharmaceutical division of Merck KGaA , announced that a license agreement has been signed with the Spanish National Cancer Research Centre, or CNIO, in Madrid in the area of cancer drug development. Under the terms of the license agreement, CNIO has granted to Merck exclusive rights to develop and commercialize their new inhibitors of the ataxia telangiectasia and Rad3-related kinase. In exchange, Merck will make an initial payment along with other potential income of up to nearly EUR19M, as well as royalties on net sales. The agreement encompasses the licensing of two series of ATR inhibitors, as well as a screening platform to validate the compounds, which have currently reached an advanced preclinical stage.
News For MKGAY From The Last 14 Days
Check below for free stories on MKGAY the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 7, 2014
06:13 EDTMKGAYOncothyreon announces Merck KGaA initiation of Phase 3 START2 study
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use